首页 | 本学科首页   官方微博 | 高级检索  
检索        


Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole
Authors:Yamagishi Hatsushi  Koike Tomoyuki  Ohara Shuichi  Horii Toru  Kikuchi Ryousuke  Kobayashi Shigeyuki  Abe Yasuhiko  Iijima Katsunori  Imatani Akira  Suzuki Kaori  Hishinuma Takanori  Goto Junichi  Shimosegawa Tooru
Institution:1. Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendal 9808574, Japan
2. Division of Clinical Pharmacy,Tohoku University Graduate School of Pharmaceutical Sciences,Sendal 9808574, Japan
3. Division of Pharmacotherapy, Tohoku University Graduate School of Pharmaceutical Sciences, and Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendal 9808574, Japan
Abstract:AIM: To compare the antisecretory activity and plasma drug concentrations of a single oral dose of 10 mg lafutidine, a novel H2 receptor antagonist, with those of the proton pump inhibitor lansoprazole (LPZ) 30 mg.METHODS: Ten volunteers without H pylori infection participated in this crossover study comparing lafutidine 10 mg with LPZ 30 mg. Intragastric pH was monitored for 6 h in all participants, and blood samples were collected from four randomly selected individuals after single-dose administration of each drug.RESULTS: The median intragastric pH was significantly higher in individuals who received lafutidine 10 mg than in those who received LPZ 30 mg 2, 3, 4, 5, and 6 h after administration. Maximal plasma drug concentration was reached more promptly with lafutidine 10 mg than with LPZ 30 mg.CONCLUSION: In H pylori-negative individuals, gastric acid secretion is more markedly inhibited by lafutidine than by LPZ.
Keywords:Lafutidine  Lansoprazole  H2 receptor antagonists  Proton pump inhibitors  Antisecretory activity
本文献已被 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号